Low-dose ruxolitinib shows effective in treating myelofibrosis

The aim of this study was to investigate the effect of low-dose ruxolitinib (daily dose ≤ 10 mg) for the treatment of myelofibrosis (MF). A retrospective analysis was performed on a total of 88 patients with myeloproliferative neoplasm-associated MF (MPN-MF) who were diagnosed and treated in West Ch...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of hematology 2021, Vol.100 (1), p.135-141
Hauptverfasser:	Yang, Yunfan, Luo, Hongmei, Zheng, Yuhuan, Zou, Zhongqing, Niu, Ting, Jia, Yongqian, Zhu, Huanling, Liu, Ting, Wu, Yu, Chang, Hong, Ji, Jie, Li, Jian, Pan, Ling
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Dose-Response Relationship, Drug Female Hematology Humans Inhibitor drugs Janus Kinase Inhibitors - administration & dosage Male Medicine Medicine & Public Health Middle Aged Oncology Original Article Primary Myelofibrosis - drug therapy Primary Myelofibrosis - pathology Pyrazoles - administration & dosage Retrospective Studies Spleen - drug effects Spleen - pathology Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!